Vernalis looks for licensing and acquisition deals after positive 2009
This article was originally published in Scrip
Executive Summary
Vernalis is keen to sign acquisition and in-licensing deals this year, in its core therapeutic focus areas of oncology and CNS (in particular, pain and neurology). "We are focusing on opportunities that won't require additional fundraising," CEO Ian Garland told Scrip, although he said that "if an opportunity came up that was very good for investors" then the possibility could be raised.